Ariad Retreats From Europe Via Incyte Deal
Executive Summary
Ariad Pharmaceuticals Inc., a company which has been plagued by setbacks for its leading marketed product, Iclusig (ponatinib), has completed the sale of its European business to Incyte Corp. for $140m.
You may also be interested in...
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.
Ariad Narrows Geographic Reach To Maximize Commercial Resources
The biotech has been streamlining its operations through licensing deals and changing its R&D strategy to better reflect its new geographic makeup – moves that could make it attractive to buyers.